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Pathophysiology of renal fluid retention. Central to a unifying
hypothesis of body fluid regulation is maintenance of arterial
circulatory integrity. This may be disturbed by arterial underfill-
ing, either from reduction in cardiac output or by peripheral
arterial vasodilation. In cardiac failure (CF), cardiac output falls
and the nonosmotic release of arginine vasopressin (AVP) and
expression of AVP mRNA in the hypothalamus are stimulated.
V2 AVP receptor antagonists correct the impaired water excre-
tion in rats with low-output CF, increase solute free water
clearance, correct the hyponatremia in congestive CF patients,
and normalize urinary concentrations of the aquaporin-2 (AQP-2)
water channels. In conditions associated with peripheral vasodi-
lation, such as cirrhosis, nonosmotic release of AVP also occurs,
and AQP-2 gene expression in the rat kidney is up-regulated. In
cirrhosis, nitric oxide-mediated vasodilation occurs early prior to
water retention. V2 antagonists reverse the latter. In normal
pregnancy, plasma AVP is relatively high for the degree of
hypoosmolality. Pregnant rats up-regulate AQP-2 in the renal
papilla, an effect reversed by V2 receptor antagonists. This
supports the hypothesis that AVP is an important mediator of
renal water retention in pregnancy. In summary, AVP-mediated
water retention through collecting duct AQP-2 water channels is
important in both low-output CF and high-output states such as
cirrhosis and pregnancy. V2 receptor antagonists reverse the
water retention and down-regulate AQP-2 water channels.
Body fluid volume regulation is a complex process re-
quiring interaction of a variety of afferent (sensory) and
neurohumoral efferent (effector) mechanisms. Central to a
unifying hypothesis of body fluid regulation is the mainte-
nance of arterial circulatory integrity [1]. Arterial circula-
tory integrity can be disturbed by either a reduction of
cardiac output, as in congestive cardiac failure (CF), or
peripheral vasodilation, as in high-output states such as
high-output CF, cirrhosis, and normal pregnancy. This
review concentrates on water retention in these conditions
including evidence for nonosmotic arginine vasopressin
(AVP) release, excessive AVP synthesis, and changes in
aquaporin-2 (AQP-2) water channels in the apical mem-
brane of the collecting duct (CD). The use of AVP V2
receptor antagonists in animals and humans is reviewed in
the context of these water-retaining conditions.
OSMOTIC AND NONOSMOTIC REGULATION OF
WATER EXCRETION
Changes in the integrity of the arterial circulation are
sensed by receptors in the left ventricle, carotid artery,
aortic arch, and afferent arterioles of the kidney. Impulses
from these receptors are conducted via the autonomic
nervous system along glossopharyngeal and vagal pathways
to the nucleus of the tractus solitarus then to the supraoptic
and paraventricular nuclei of the hypothalamus. It is this
reflex that senses arterial underfilling and results in nonos-
motic AVP release from the posterior pituitary. The AVP
gene in the hypothalamus has been cloned [2] and has three
exons that encode for a signal peptide, AVP, a neurophy-
sin-binding protein, and a glycopeptide. Cleavage of the
signal peptide leaves a prohormone that is packaged in
neurovesicles, undergoes proteolytic cleavage, and is trans-
ported down neural axons to the posterior pituitary, where
AVP, neurophysin, and the glycopeptide are released in
response to either osmotic or nonosmotic stimuli.
The actions of AVP are mediated through AVP recep-
tors. There are at least three distinct types–V1a, V1b, and
V2–that have been cloned and sequenced [3–5]. Classic
smooth muscle cell contraction, platelet aggregation, and
hepatic glycogenolysis actions are mediated through the
V1a receptor. V2 receptors are expressed in the basolateral
cell membrane of CD principal cells [6]. The V2 receptor is
G protein linked with seven transmembrane domains.
Activation of CD V2 receptors by AVP increases apical
membrane permeability to water. Specifically, AVP induces
translocation of cytoplasmic vesicles containing AQP-2
water channels to the apical membrane coincident with the
increase in membrane water permeability. This phenome-
non has been termed the shuttle hypothesis [7]. It is now
clear that AQP-2 is the AVP-sensitive water channel in the
CD [8]. Studies have shown AVP-induced translocation of
AQP-2-containing vesicles to the apical membrane with a
simultaneous increase in CD water permeability [9]. AVP
regulates CD water permeability in two ways. First, there is
a short-term increase in CD water permeability over a few
minutes, which is associated with shuttling of AQP-2 water
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channels from intracellular vesicles into the apical plasma
membrane via exocytosis [9]. Long-term regulation follows
when AVP concentrations are elevated for 24 hours or
more. This leads to an AVP-induced increase in the
quantity of AQP-2 water channels in CD principal cells [10,
11].
WATER RETENTION IN CARDIC FAILURE
Early animal studies, prior to the availability of a sensi-
tive AVP radioimmunoassay, indirectly implicated AVP in
the mechanism of water retention in CF. In a dog experi-
ment with CF induced by thoracic vena caval constriction,
surgical hypophysectomy, and hence AVP deficiency, vir-
tually abolished the defect in water retention [12]. Simi-
larly, the impaired water excretion in rats with high-output
CF cannot be reproduced in animals with central diabetes
insipidus [13]. Radioimmunoassay demonstrated elevated
plasma AVP in congestive CF [14–18]. In an early such
study, 30 out of 37 hyponatremic patients with CF had
detectable plasma AVP concentrations [14]. In normal
subjects, this degree of hypoosmolality would have been
suppressed AVP release, thus supporting nonosmotic AVP
release in CF. Plasma AVP also correlates with the severity
of CF [15] and the degree of hyponatremia [16]. The
removal of excess body fluid in patients with CF using
hemofiltration reverses the increased plasma AVP and
improves the clinical picture [15]. This finding further
supports the hypothesis of nonosmotic AVP release sec-
ondary to loss of arterial circulatory integrity. Using a
cDNA probe for AVP in rats with CF showed the elevated
plasma AVP to be associated with a significant increase in
hypothalamic AVP mRNA [19].
ARGININE VASOPRESSIN V2 RECEPTOR
ANTAGONISTS
Potent peptide V2 receptor antagonists have been avail-
able since the 1980s [20], but unfortunately, they were not
clinically useful because of low oral bioavailability and their
partial agonist effects in humans. The first nonpeptide,
orally active V2 receptor antagonist, OPC-31260, was de-
scribed in 1992 [21]. These V2 receptor antagonists have
been used to assess the role of AVP in CF. In the rat with
low-output CF secondary to thoracic vena caval constric-
tion, plasma AVP concentrations were increased, and a V2
peptide receptor antagonist reversed the defect in water
excretion [22]. In another model in the rat with CF
secondary to left coronary artery ligation, a nonpeptide V2
receptor antagonist also reversed the defect in water reten-
tion [23]. The V2 antagonist OPC-31260 given to dogs with
CF secondary to ventricular pacing [24] and to rats with
experimental CF from myocardial infarction [25] reversed
the impaired water excretion. In a rat model of low-output
CF from left coronary artery ligation, administration of the
V2 receptor antagonist OPC-31260 induced significant
diuresis, decreased urinary osmolality, and raised plasma
osmolality [26]. CD AQP-2 mRNA and protein are ele-
vated in these CF rats and are reduced significantly when
these rats are treated with OPC-31260. These studies
therefore confirm the efficacy of V2 antagonists in revers-
ing the water retention in low-output CF and support the
hypothesis that AVP-mediated water retention is a major
factor in CF. The latter study, demonstrating up-regulation
of AQP-2 mRNA and protein in rats with CF and its
reversal by a V2 receptor antagonist, indicates a major role
for AVP-regulated water channels in experimental CF [26].
The orally active, nonpeptide, selective V2 receptor
antagonist WAY-VPA-985 has been used in humans with
congestive CF in a randomized, double-blind, placebo-
controlled ascending single-dose study [27]. At all doses,
WAY-VPA-985 increased urine flow and serum [Na] and
elicited significant dose-related reductions in urinary osmo-
lality, thus indicating an increase in solute-free water
clearance. This finding supports a major role of plasma
AVP in the impaired water excretion in humans with CF.
Moreover, it indicates that these aquaretic agents may have
a major clinical role in the treatment of water retention in
CF.
WATER RETENTION IN CIRRHOSIS
Severe liver disease with cirrhosis and ascites is associ-
ated with water retention, an increase in total body water,
and dilutional hyponatremia [28]. Of patients with cirrhosis
and ascites, 30% will have hyponatremia [29], a finding that
is associated with significant morbidity and mortality [30].
The ability to excrete an acute water load is maintained in
compensated cirrhotic patients without ascites; however,
decompensated cirrhotic patients with ascites have a re-
duced ability to excrete a water load [28, 31–33]. AVP has
a significant role in the pathogenesis of water retention in
cirrhosis with ascites. This has been demonstrated in both
human and animal studies. In a study of cirrhotic patients
with ascites, the patients could be categorized according to
the response to a standard water load [34]. Nonexcretors
failed to excrete 80% of the water load over five hours,
whereas excretors did. The nonexcretors were unable to
suppress plasma AVP after the water load, and there was a
significant correlation between plasma AVP after the water
load and the percentage of water load excreted. In another
study, nonexcretors had significantly higher concentrations
of plasma norepinephrine, renin, aldosterone, and AVP
[35]. These studies support a role for nonosmotic AVP
release in decompensated cirrhotic patients with ascites.
Animal studies provide further support for this conclusion
[36–40]. In rats with experimental cirrhosis and ascites, the
defect in water excretion correlated both chronologically
and quantitatively with the elevated plasma AVP [36]. Induc-
tion of cirrhosis in Brattleboro rats, a strain with congenital
AVP deficiency, is not associated with impaired water
excretion [37]. Support for an increased production of AVP
was the demonstration of increased AVP mRNA in the
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hypothalamus of cirrhotic rats [38]. With the availability of
AVP V2 receptor antagonists, it has also been shown that
these agents can restore the ability to excrete water in
cirrhotic rats [39]. Moreover, AQP-2 water channel expres-
sion is increased in cirrhotic rats with ascites [40]. The
increased expression of AQP-2 is not suppressed by a water
load but is decreased by prior administration of the AVP
V2 receptor antagonist, OPC-31260. A study is currently
underway assessing an orally active, nonpeptide AVP V2
receptor antagonist in humans with hyponatremia second-
ary to liver disease.
The stimulus for nonosmotic production and release of
AVP in cirrhosis is arterial underfilling initiated by primary
arterial vasodilation [41]. Although the pathogenesis of the
peripheral vasodilation is not fully understood, there is
evidence for a major role for NO [42]. Increased vascular
NO production has been demonstrated in cirrhosis [43]. In
a rat model of cirrhosis, the use of a nitric oxide synthase
(NOS) inhibitor to normalize vascular NO production
corrected the hyperdynamic circulation, decreased neuro-
humoral activation, and improved sodium and water excre-
tion [44, 45]. The importance of plasma AVP and angio-
tensin II (Ang II) in stabilizing hemodynamics was
demonstrated in a study of cirrhotic rats with ascites [46].
Administration of saralasin, an Ang II blocker, and a V1
receptor antagonist to cirrhotic rats reduced blood pres-
sure, and when given together, these agents had an additive
effect, whereas there was no effect in control animals.
These findings support the role of both Ang II and AVP in
the maintenance of blood pressure in cirrhotic animals as a
compensatory response to the arterial vasodilation that is
primarily in the splanchnic circulation.
WATER RETENTION IN NORMAL PREGNANCY
Normal human pregnancy results in an increase in total
body water (TBW) of 6 to 8 liters [47]. Measurements of
TBW and Na have shown that the relative increase in TBW
is greater than that of Na [48]. Plasma osmolality falls by 8
to 10 mOsm/kg below nonpregnant values by 10 weeks of
pregnancy and this is maintained until term [49]. Studies in
rats and humans have demonstrated that the osmotic
threshold for AVP release is reset at a lower level in
pregnancy, whereas the sensitivity of the AVP response is
unaltered [50]. The osmotic threshold for thirst also de-
creases in parallel with the AVP release in pregnancy [51].
Gravidas therefore concentrate and dilute their urine
around a plasma osmolality 10 mOsm/kg below nonpreg-
nant values [52]. There is a substantial rise in the metabolic
clearance rate of AVP coincident with marked increases in
the circulating concentrations of vasopressinase, a placen-
tal enzyme induced during pregnancy [52]. Although
plasma AVP is generally not detectably elevated in preg-
nancy, it is relatively high for the degree of plasma hypoos-
molality. The water retention seen in pregnancy occurs in
association with a rise in cardiac output of 30% to 50% and
a rise in glomerular filtration rate of 30% to 50% [53]. In a
study of pregnant baboons, the early hemodynamic changes
included a rise in cardiac output, a decrease in systemic
vascular resistance, and a fall in blood pressure [54]. These
same hemodynamic responses also occur early in human
pregnancy. The release of a circulating vasodilator has been
suggested to initiate the fall in systemic vascular resistance,
and hence arterial underfilling stimulates the nonosmotic
release of AVP with the concomitant occurrence of hy-
poosmolality [55]. A variety of vasodilators have been
proposed as potential mediators of the fall in systemic
vascular resistance, such as vasodilatory prostaglandins
including prostaglandin E (PGE)2 and prostacyclin (PGI2)
[56]. NO is also released by the endothelium and has potent
vasorelaxing effects. The calcium-dependent NOS in the
endothelium is also stimulated by estrogen [57]. NO pro-
duction has been shown to be increased during pregnancy
in rats [58]. A recent study in pregnant rats has also shown
the up-regulation of the constitutive NOS isoforms endo-
thelial NOS (eNOS) and neuronal NOS (nNOS). Specifi-
cally, eNOS was increased in the aorta and mesenteric
artery of pregnant rats. Furthermore, nNOS was increased
in the hypothalamus, in parallel with a rise in AVP mRNA
in the pregnant rat [59]. It is possible that the up-regulated
eNOS and nNOS both could contribute to AVP release,
eNOS secondarily by mediating the peripheral arterial
vasodilation and subsequent nonosmotic AVP release and
nNOS by a direct effect on the hypothalamus. Further
support for the role of AVP in the water retention in
pregnancy comes from a recent study in pregnant rats
showing up-regulation of the CD water channel AQP-2
mRNA and protein [60]. Administration of the V2 receptor
antagonist OPC-31260 decreased expression of AQP-2
mRNA and protein to the same level seen in nonpregnant
rats. Interestingly, plasma AVP was not different in preg-
nant rats compared with nonpregnant rats; however, the
concentrations in the pregnant rats were relatively high for
the degree of hypoosmolality. Nevertheless, although stim-
ulation of V2 receptors by AVP is a likely explanation for
AQP-2 up-regulation, other possibilities such as oxytocin
[61, 62] need to be considered. Also of interest is the
persistence of hypoosmolality in pregnant rats receiving a
V2 receptor antagonist, indicating that factors other than
AVP are involved. The increased thirst and water intake of
pregnancy is one such potential factor.
CONCLUSION
Nonosmotic stimulated, AVP-mediated water retention
is a significant contributor to water retention in low cardiac
output CF and high cardiac output states associated with
peripheral vasodilation such as cirrhosis and pregnancy.
Studies of the CD water channel AQP-2 have assisted in
the understanding of water retention in these conditions, as
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has the development of AVP V2 receptor antagonists (Fig.
1). These drugs, now available in nonpeptide orally active
form, have shown promising clinical results in hyponatre-
mic patients with CF. A study using a V2 receptor antag-
onist in patients with liver disease and hyponatremia is
currently in progress.
APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; AQP-2,
aquaporin-2; AVP, arginine vasopressin; CD, collecting duct; CF, cardiac
failure; eNOS, endothelial NOS; NOS, nitric oxide synthase; nNOS,
neuronal NOS; PGE, prostaglandin E; PGI2, prostacyclin; TBW, total
body water.
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